19 January 2024, Israel: Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that the final patient has been enrolled in its Phase I clinical trial.
Initiated on July 11, 2022, the Phase I trial was specifically designed to evaluate the safety and tolerability of Biomica’s microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who previously progressed on immunotherapy. Bristol Myers Squibb’s Opdivo® is the immune checkpoint inhibitor in the trial. The study takes place at The Davidoff Center and the Rambam Health Care Campus in Israel.
Biomica remains on track with preliminary results, and the first data point readout is expected in H1 2024.
Dr. Elran Haber, CEO of Biomica, stated: “We are pleased to complete the Phase 1 Proof of Concept study enrollment, marking a critical step forward in developing our groundbreaking BMC128. We are excited about the progress made thus far and confident about the potential of BMC128 to address the unmet needs in the treatment of ICI-refractory cancer patients.”
(For Latest Agriculture News & Updates, follow Krishak Jagat on Google News)